Aralkyl ester soft drugs

Details Aralkyl ester soft drugs Aralkyl ester soft drugs

2007-01-16

2007-01-16

Stockton, Laura L. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

10857683

ABSTRACT:
The present invention describes a method for programming a specific course and rate of metabolism for a parent drug compound that leads to an inactive or very weakly active and nontoxic metabolite when the modified drug compound is administered. The parent drug compound is modified by forming one or more of a predetermined chemical arrangement within the parent drug structure where the chemical arrangement is A-Ø-(R)—X—R′; where A is absent or is a tether moiety which allows for a metabolically stable chemical connection to be made to the parent drug compound; Ø is a substituted aryl or heteroaryl system that is already present within the parent drug compound or is specifically added to the parent drug compound via A; R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is either also already present within the parent drug compound or is specifically added to the parent drug compound via connection to Ø; X is a carboxyl, sulfoxyl or phosphatyl function that is specifically added to the parent drug compound via connection to R; and, R′ is an added alkyl, alkenyl, or aralkyl group either branched or unbranched containing from 1 to 10 carbons, other common leaving group, or a structural element already present as an inherent portion of the parent drug compound.

REFERENCES:
patent: 3150137 (1964-09-01), Buzas
patent: 3636010 (1972-01-01), Anner et al.
patent: 4093721 (1978-06-01), Phillipps et al.
patent: 4163058 (1979-07-01), Stella et al.
patent: 4304781 (1981-12-01), Crossley
patent: 4387103 (1983-06-01), Erhardt et al.
patent: 4405642 (1983-09-01), Kam et al.
patent: 4450173 (1984-05-01), Erhardt et al.
patent: 4505926 (1985-03-01), Newsome et al.
patent: 4508725 (1985-04-01), Matier et al.
patent: 4556668 (1985-12-01), Erhardt et al.
patent: 4593119 (1986-06-01), Erhardt et al.
patent: 4604481 (1986-08-01), Kam et al.
patent: 4623652 (1986-11-01), Erhardt et al.
patent: 4692446 (1987-09-01), Erhardt et al.
patent: 4804677 (1989-02-01), Erhardt et al.
patent: 4906661 (1990-03-01), Erhardt et al.
patent: 4929623 (1990-05-01), Abe et al.
patent: 5849788 (1998-12-01), Druzgala
patent: 6114344 (2000-09-01), Druzgala et al.
patent: 6130240 (2000-10-01), Druzgala
patent: 6159665 (2000-12-01), Chin et al.
patent: 6316487 (2001-11-01), Druzgala et al.
patent: 6362223 (2002-03-01), Druzgala et al.
patent: 6372783 (2002-04-01), Druzgala et al.
patent: 6387914 (2002-05-01), Druzgala et al.
patent: 6469064 (2002-10-01), Druzgala
patent: 2001/0056119 (2001-12-01), Druzgala et al.
patent: 2002/0013330 (2002-01-01), Druzgala et al.
patent: 2002/0025970 (2002-02-01), Druzgala et al.
patent: 2002/0045620 (2002-04-01), Druzgala et al.
patent: 2002/0143002 (2002-10-01), Hochberg
patent: 2002/0169208 (2002-11-01), Druzgala
patent: 2002/0183343 (2002-12-01), Druzgala
patent: 2002/0193428 (2002-12-01), Druzgala et al.
patent: 0 640 601 (1995-03-01), None
patent: 0 703 910 (1996-04-01), None
patent: WO 02/40052 (2002-05-01), None
patent: WO 02/096855 (2002-12-01), None
Fetter et al., Acta Chimica Academiae Scientiarum Hungaricae (1973), 78(3), pp. 325-333.
N. Bodor and P Buchwald; Drug Targeting via Retrometabolic Approaches; Pharmacol. Ther. vol. 76, Nos. 1-3, pp. 1-27, (1997).
R. Albrecht and O. Loge; B2-Agonists containing metabolically labile groups II. The influence of ester groups in the aryl system. Eur. J. Med.Chem-Chim Ther. 20. N 1, pp. 57-60 (1989).
A. Juhasz and N. Bodor; Cardiovascular studies on different classes of soft drugs; Parmazie 55:228-238 (2000).
M.J. Pekka Raatikainen, C.A. Napolitano, P. Druzgala and D.M. Dennis; Electrophysiological Effects of a Novel, Short-Acting and Potent Ester Derivative of Amiodarone, ATI-2001, in Guinea Pig Isolated Heart; The Journal of Pharmacology and Experimental Therapeutics; vol. 227, No. 3, pp. 1454-1463 (1996).
T.E. Morey, C.N. Seubert, M.J. Pekka Raatikainen, A.E. Martynyuk; P. Druzgala, P. Milner, M.D. Gonzalez and D.M. Dennis; Structure-Activity Relationships and Electrophysiological Effects of Short-Acting Amiodarone Homologs in Guinea Pig Isolated Heart; The Journal of Pharmacology and Experimental Therapeutics, vol. 297, No. 1, pp. 260-266 (2001).
M.J. Pekka Raatikainen, T.E. Morey, P. Druzgala, P. Milner, M.D. Gonzalez, and D.M. Dennis; Potent and Reversible Effects of ATI-2001 on Atrial and Atrioventricular Nodal Electrophysiological Properties in Guinea Pig Isolated Perfused Heart; The Journal of Pharmacology and Experimental Therapeutics; vol. 295, No. 2, pp. 779-785 (2000).
R. Albrecht and O. Loge; B2—Agonists containing metabolically labile groups. I. The influence of ester groups in the nitrogen substituent; Eur. J. Med. Chem.-Chim. Ther. 20., No., pp. 51-55 (1985).
O. Rosen and F. Sandberg; Studies on N-Substituted Barbituric Acid Derivatives. II; Acta Chemica Scandinavica 675-687 (1950).
H.-S. Yang, W.-M. Wu and N. Bodor, Soft Drugs. XX. Design, Synthesis, and Evaluation of Ultra-Short Acting beta-Blockers,Pharm. Res., 12, 329-336 (1995).
M. Graffner-Nordberg, K. Sjodin, A. Tunek and A. Halberg, Synthesis and Enzymatic Hydrolysis of Esters, Constituting Simple Models of Soft Drugs,Chem.Pharm.Bull., 46, 591-601 (1998).
R.M. Long and R.M. Weishilbourn, Recommendations of the NIGMS Working Group-Understanding Individual Variations in Drug Responses: From Phenotype to Genotype,NIH Reporthttp://www.hih.gov
igms
ews/reports/pharmaceogentics.html, 5 pages (Jun. 9-10, 1998).
P.W. Erhard, Benzylamine and Dibenzylamine Rvisited. Syntheses of N-Substituted Aryloxypropanolamines Exemplifying a General Route to Secondary Aliphatic Amines,Synth. Comm., 13, 103-113 (1983).
P.W. Erhardt, C.M. Woo, W.G. Anderson and R.J. Gorcynski, Ultra Short-Acting β-Adrenergic Receptor Blocking Agents. 2. (Aryloxy)propanolamines Containing Esters in the Aryl Function,J.Med.Chem., 25, 1408-1412 (1982).
P.W. Erhardt, C.M. Woo, W.L. Matier, R.J. Gorcynski and W.G. Anderson, Ultra-Short-Acting β-Adrenergic Receptor Blocking Agents. 3. Ethylenediamine Derivatives of (Aryloxy)propanolamines Having Esters on the Aryl Function,J.Med.Chem., 26, 1109-1112 (1983).
P.W. Erhardt,Esmolol. InChronicles of Drug Discovery, D. Lednicer, Ed. ACS Books, Washington D.C., U.S.A. 191-206 (1993).
P.W. Erhardt, A Prodrug and a Soft Drug. P.W. Erhardt, inDrug Metabolism: Databases and High-Throughput Testing During Drug Design and Development, Ed. IUPAC Books, Blackwell Science, Oxford, U.K., 62-69 (1999).
D.M. Stout, L.A. Black, C.L. Barcelon-Yang, W.L. Matier, B.S. Brown, C.Y. Quon and H.F. Stampfli, Ester Derivatives of 2,6-Bis (1-pyrrolidinylmethyl)-4-benzamidophenol as Short-Acting Antiarrhythmic Agents. 1.,J.Med.Chem., 32, 1910-1913 (1989).
R.J. Chorvat, L.A. Black, V.V. Ranade, C. Barcelon-Yang, D.M. Stout, B.S. Brown, H.F. Stampfli and C.Y. Quon Mono and Bis(aminomethyl)phenylacetic Acid Esters as Short-Acting Antiarrhythmic Agents. 2.,J.Med.Chem., 36, 2494-2498 (1993).
P.W. Erhardt, Drug Metabolism Data: Past, Present, and Future Considerations,Med.Chem.Res., 8, 400-421 (1998).
P.W. Erhardt, Drub Metabolism Data: Past Present and Future Considerations,Metabolism Databases and High Through-put Testing During Drug Design and Development, Ed. IUPAC Books, Blackwell Science, Oxford, U.K. 2-15 (1999).
P.W. Erhardt, Statistics-Based Probabilities of Metabolic Possibilities,Metabolism Databases and High Through-put Testing During Drug Design and Development, Ed. IUPAC Books, Blackwell Science, Oxford, U.K., 185-191 (1990).
P.W. Erhardt, Comparison of Commercially Available Metabolism Databases During The Design of Prodrugs and Codrugs,Metabolism Databases and High Through-put Testing During Drug Design and Development, Ed. IUPAC Books, Blackwell Science, Oxford, U.K., 208-222 (1999).
P. Buchwald and N. Bodor, Quantitative Structure-Metabolism Relationships: Steric and Nonsteric Effects in the Enzymatic Hydrolysis of Noncongener Carboxylic Esters,J.Med.Chem., 42, 5160-5167 (1999).
N.C. Dhar, R.B. Maehr, L.A. Masterson, J.M. Midgley, J.B. Stenlake and W.B. Wastila, Approaches

Affiliated with

Also associated with

Rating

Aralkyl ester soft drugs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aralkyl ester soft drugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aralkyl ester soft drugs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3798781